JP2021517129A5 - - Google Patents
Info
- Publication number
- JP2021517129A5 JP2021517129A5 JP2020546926A JP2020546926A JP2021517129A5 JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5 JP 2020546926 A JP2020546926 A JP 2020546926A JP 2020546926 A JP2020546926 A JP 2020546926A JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US62/639,587 | 2018-03-07 | ||
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| US62/807,912 | 2019-02-20 | ||
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517129A JP2021517129A (ja) | 2021-07-15 |
| JP2021517129A5 true JP2021517129A5 (OSRAM) | 2022-03-11 |
| JP7312188B2 JP7312188B2 (ja) | 2023-07-20 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546926A Active JP7312188B2 (ja) | 2018-03-07 | 2019-03-04 | 抗ｐｄ－１抗体組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (OSRAM) |
| EP (1) | EP3761954A1 (OSRAM) |
| JP (1) | JP7312188B2 (OSRAM) |
| KR (1) | KR102594028B1 (OSRAM) |
| CN (1) | CN112105343B (OSRAM) |
| AU (1) | AU2019232625B2 (OSRAM) |
| BR (1) | BR112020017935A2 (OSRAM) |
| IL (1) | IL277095B2 (OSRAM) |
| MX (1) | MX2020009275A (OSRAM) |
| WO (1) | WO2019171253A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CA3160806A1 (en) * | 2019-11-13 | 2021-05-20 | Pfizer Inc. | Stable aqueous formulation containing anti-tfpi antibody _______ |
| EP4074338A4 (en) * | 2019-12-13 | 2024-03-06 | Samsung Bioepis Co., Ltd. | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN115397394A (zh) * | 2020-01-31 | 2022-11-25 | 赛诺菲 | 抗体的肺部递送 |
| MA59827B1 (fr) | 2020-05-26 | 2024-10-31 | Boehringer Ingelheim International Gmbh | Anticorps anti-pd-1 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| EP4359001A1 (en) | 2021-06-23 | 2024-05-01 | Formycon AG | Formulations of anti-pd1 antibodies |
| WO2023274275A1 (zh) * | 2021-07-01 | 2023-01-05 | 天津立博美华基因科技有限责任公司 | 药物组合及其用途 |
| PE20240797A1 (es) * | 2021-07-09 | 2024-04-18 | Macrogenics Inc | Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas |
| EP4395816A4 (en) * | 2021-09-03 | 2025-07-30 | Dr Reddys Laboratories Ltd | PHARMACEUTICAL FORMULATION OF IMMUNE CHECKPOINT INHIBITORS |
| EP4395815A4 (en) * | 2021-09-03 | 2025-07-30 | Dr Reddys Laboratories Ltd | METHOD FOR IMPROVING THE STABILITY OF IMMUNE CHECKPOINT INHIBITORS |
| AU2023229902A1 (en) * | 2022-03-07 | 2024-08-29 | Mabxience Research, S.L. | Stable formulations for antibodies |
| EP4637818A1 (en) | 2022-12-21 | 2025-10-29 | Formycon AG | Formulations of anti-pd1 antibodies |
| IL322410A (en) | 2023-02-16 | 2025-09-01 | Sun Pharmaceutical Ind Ltd | Stable protein complexes containing an antibody against PD1 |
| KR20260054696A (ko) * | 2023-08-16 | 2026-04-22 | 상하이 맙젠 바이오텍 리미티드 | 면역접합체를 포함하는 약학적 조성물 및 이의 용도 |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| LT2620450T (lt) * | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| CN101146553A (zh) * | 2005-03-23 | 2008-03-19 | 辉瑞产品公司 | 用于治疗癌症的抗-ctla4抗体和吲哚酮组合治疗 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EA201291181A1 (ru) * | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
| SG193964A1 (en) | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| DK3049441T3 (da) * | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| TW202214691A (zh) * | 2014-03-21 | 2022-04-16 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| AU2016210918A1 (en) * | 2015-01-28 | 2017-07-13 | Pfizer Inc., | Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation |
| MX395336B (es) * | 2015-09-28 | 2025-03-25 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| CA3061050A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| WO2018211517A1 (en) * | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/ko active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/ja active Active
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/pt unknown
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/zh active Active
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/es unknown
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7842070B2 (ja) | 抗ｃｄ３８抗体の皮下製剤及びその使用 | |
| JP2024102215A5 (OSRAM) | ||
| JP2020518600A5 (OSRAM) | ||
| JP2021524256A5 (OSRAM) | ||
| RS56210B1 (sr) | Formulacije sa visokom koncentracijom antitela | |
| BR112019022698A2 (pt) | formulações estáveis de anticorpos anti-tigit isolados e em combinação com anticorpos do receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
| JP2018503365A5 (OSRAM) | ||
| CN107252485A (zh) | 用于诱导对疾病的免疫应答的组合疗法 | |
| JP2015500207A5 (OSRAM) | ||
| US8992915B2 (en) | Combination of CD37 antibodies with ICE | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| JP7448552B2 (ja) | がんの併用療法 | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| KR20250004789A (ko) | Pd-1 항체를 함유하는 안정한 고농도 아르기닌 제제 및 그의 사용 방법 | |
| CN119584995A (zh) | 组合疗法 | |
| RU2020129226A (ru) | Композиции анти-pd-1 антител | |
| EP4722240A1 (en) | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof | |
| WO2025244529A1 (en) | Dosing regimen of an egfr binding and/or complement activating antibody | |
| TW202612730A (zh) | Ｅｇｆｒ結合和／或補體活化抗體的給藥方案 | |
| HK40126447A (zh) | 抗cd38抗体的皮下制剂及其用途 | |
| WO2025072516A1 (en) | Methods of reducing weight loss using anti-gdf15 antibodies | |
| CN115944741A (zh) | 含TGF-β受体的融合蛋白与紫杉类、核苷类似物联合在制备治疗胰腺癌药物中的用途 | |
| HK40041199B (zh) | 抗-pd-1抗体组合物 | |
| EA053009B1 (ru) | Составы антител к cd38 для подкожного введения и их применение |